<ul>
<li>Keros Therapeutics director Jean Jacques Bienaime bought 1,000 common shares at a weighted average price of $10.58.     *      Direct holdings rose to 9,450 shares following the purchase. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001221590-26-000009), on May 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</li>
</ul>

KROS

IBBQ

LABU

SBIO

<p>Keros Therapeutics director Jean Jacques Bienaime acquired 1,000 common shares at a weighted average price of $10.58, increasing his total holdings to 9,450 shares.</p>

PUBT

Keros Therapeutics

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Keros director Jean Jacques Bienaime acquires $10,580 common shares